Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-07-27 | Reverse | 1:50 |
| 2023-02-13 | Reverse | 1:18 |
| 2021-02-16 | Reverse | 1:4 |
Yarrow Bioscience is a clinical-stage biotech developing YB-101, a first-in-class anti-TSHR monoclonal antibody targeting autoimmune thyroid diseases like Graves' disease and thyroid eye disease.

YB-101 is a clinical-stage monoclonal antibody targeting TSHR, in Phase 2 trials for autoimmune thyroid diseases like Graves' disease and TED.
| Icon | PRODUCT | Q2-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | Reportable Segment | $69K | $299K ▲ | $86K ▼ | $97K ▲ |
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
XTLB | $2.78 | COMPARE |
KTTA | $0.54 | COMPARE |
KALA | $0.82 | COMPARE |
QNRX | $5.57 | COMPARE |
BCLI | $0.98 | COMPARE |
SNGX | $0.40 | COMPARE |
ENSC | $0.37 | COMPARE |
TCRT | $1.76 | COMPARE |